Suicide-gene-transduced donor T-cells for controlled graft-versus-host disease and graft-versus-tumor

International Journal of Hematology

Volumn 76, Issue 4, 2002, Pages 305-309

  Ciceri, Fabio ^a,b   Bordignon, Claudio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b C G Bone Marrow Transplant U   (Italy)

Author keywords

Gene therapy; Graft versus tumor; Hematopoietic cell transplantation; Suicide gene

Indexed keywords

GANCICLOVIR; RECOMBINANT ENZYME; VIRUS ENZYME; THYMIDINE KINASE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RELAPSE; CANCER RISK; CELL BASED GENE THERAPY; DONOR; GENETIC MANIPULATION; GENETIC TRANSDUCTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOTYPE; HERPES SIMPLEX VIRUS; HLA MATCHING; HUMAN; LEUKEMIA; MYCOSIS; OPPORTUNISTIC INFECTION; RISK FACTOR; SUICIDE GENE; SUICIDE GENE THERAPY; T CELL DEPLETION; T LYMPHOCYTE; VIRUS INFECTION; ANIMAL; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOCYTE TRANSFUSION; METABOLISM; METHODOLOGY; REVIEW; TRANSPLANTATION;

ANIMALS; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LYMPHOCYTE TRANSFUSION; T-LYMPHOCYTES; THYMIDINE KINASE; TRANSDUCTION, GENETIC;

EID: 1242278888     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982688     Document Type: Article

References (32)

1. Ringden O, Horowitz MM, Gale RP, et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA. 1993;270:57-60.
2. Armitage JO. Bone marrow transplantation. N Engl J Med. 1994;330:827-838.
3. Klingemann HG, Storb R, Fefer A, et al. Bone marrow transplantation in patients aged 45 years and older. Blood. 1986;67:770-776.
4. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385-389.
5. Basara N, Blau IW, Willenbacher W, Kiehl MG, Fauser AA. New strategies in the treatment of graft-versus-host disease. Bone Marrow Transplant. 2000;25:S12-S15.
6. Gaziev D, Galimberti M, Lucarelli G, Polchi P. Chronic graft-versus-host disease: is there an alternative to the conventional treatment? Bone Marrow Transplant. 2000;25:689-696.
7. Barnes DWH, et al. Treatment of murine leukemia with x-rays and homologous bone marrow. BMJ. 1956;2:626-627.
8. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068-1073.
9. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.
10. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462-2465.
11. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 1995;86:2041-2050.
12. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995;86:1261-1268.
13. Collins RH, Jr., Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
14. Porter DL, Connors JM, Van Deerlin VM, et al. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol. 1999;17:1234.
15. Collins RH, Jr., Goldstein S, Giralt S, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 2000;26:511-516.
16. Schmid C, Lange C, Salat C, et al. Treatment of recurrent acute leukemia after marrow transplantation with donor cells and GM-CSF [abstract]. Blood. 1999;94 (10 suppl 1):668a. Abstract 2965.
17. Porter DL, Collins RH, Jr., Shpilberg O, et al. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant. 1999;5:253-261.
18. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood. 1997;90:4206-4211.
19. Mandigers CM, Meijerink JP, Raemaekers JM, Schattenberg AV, Mensink EJ. Graft-versus-lymphoma effect of donor leucocyte infusion shown by real- time quantitative PCR analysis of t(14;18). Lancet. 1998;352:1522-1523.
20. Dazzi F, Szydlo RM, Craddock C, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood. 2000;95:67-71.
21. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995;86:4337-4343.
22. Falkenburg JH, Wafelman AR, Joosten P, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood. 1999;94:1201-1208.
23. Bordignon C, Carlo-Stella C, Colombo MP, et al. Cell therapy: achievements and perspectives. Haematologica. 1999;84:1110-1149.
24. Bordignon C, Bonini C, Verzeletti S, et al. Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther. 1995;6:813-819.
25. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276:1719-1724.
26. Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science. 1995;270:470-475.
27. Bonini C, Ciceri F, Marktel S, Bordignon C. Suicide-gene-transduced T-cells for the regulation of the graft-versus-leukemia effect. Vox Sang. 1998;74:341-343.
28. Tiberghien P, Cahn JY, Brion A, et al. Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: a phase I-II study. Hum Gene Ther. 1997;8:615-624.
29. Tiberghien P, Ferrand C, Lioure B, et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood. 2001;97:63-72.
30. Champlin R, Besinger W, Henslee-Downey J, et al. Phase I/II study of thymidine kinase (TK)-transduced donor lymphocyte infusions (DLI) in patients with hematologic malignancies [abstract]. Blood. 1999;94:1448a.
31. Verzeletti S, Bonini C, Marktel S, et al. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum Gene Ther. 1998;9:2243-2251.
32. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186-1193.